platinum-sensitive ovarian cancer

June 18, 2020June 18, 2020

Mirvetuximab Soravtansine-Avastin Combo Linked to Promising Responses

News

When given alongside Avastin (bevacizumab), mirvetuximab soravtansine leads to promising treatment responses in women with recurrent ovarian cancer — particularly those whose tumors contain high levels of the protein folate ... Read more

January 8, 2020

Second Surgery for Recurrent Ovarian Cancer Does Not Improve Survival, Phase 3 Trial Shows

News

A second surgery followed by chemotherapy is no better than chemotherapy alone at extending the lives of women with platinum-sensitive ovarian cancer who experienced disease recurrence after a first surgery. ... Read more

December 4, 2019

Rubraca Reimbursement Approved in Italy for Women With Relapsed Platinum-sensitive Ovarian Cancer

News

The Italian Medicines Agency (AIFA) has approved Clovis Oncology’s Rubraca (rucaparib) for reimbursement in Italy as a maintenance therapy for women with relapsed ovarian cancer who responded to platinum-based chemotherapy, ... Read more

August 26, 2019

Rubraca Conditionally Rejected for Use on NHS England for Recurrent Ovarian Cancer

News

Rubraca (rucaparib), a therapy for relapsed or progressive ovarian, fallopian, or primary peritoneal cancer, was provisionally rejected for use on England’s National Health Service (NHS). In justifying its decision, the ... Read more

June 12, 2019

Rubraca Maintenance Delays Disease Progression in Subsequent Treatments for Recurrent OC, Phase 3 Trial Shows

News

Maintenance treatment with Rubraca (rucaparib) delays the need for additional treatments among women with platinum-sensitive recurrent ovarian cancer — and then extends the time to disease worsening after those subsequent ... Read more

March 27, 2019

Patients with Platinum-sensitive Ovarian Cancer Live Longer on SOTIO’s Immunotherapy, Trial Shows

News

Adding SOTIO’s ovarian cancer immunotherapy DCVAC/OvCa to standard second-line chemotherapy significantly extends the lives of women with advanced ovarian cancer who initially responded to their first-line chemotherapy, a Phase 2 ... Read more

May 11, 2018

Lynparza Tablets Approved in EU to Treat Advanced, Platinum-sensitive Ovarian Cancers

News

The European Medicines Agency (EMA) has approved Lynparza (olaparib) tablets as a maintenance therapy for ovarian cancer patient who have relapsed, but have had a complete or partial response to platinum-based chemotherapy, and ... Read more